Inhibitory effect and mechanism of epigallocatechin-3-gallate on autogenous vein graft stenosis in rat models_Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Authors：

ZHANG Yi ¹ , GU Jun ² , LIU Linbo ¹ , LIAO Zhijie ¹ , ZHANG Hongwei ² , YANG Peng ² , FAN Kangjun ² , LIANG Huaimin ² , XIAO Zhenghua ² ,  HU Jia ²

1. Department of Cardiovascular Surgery, Third Hospital of Mianyang, Mianyang, 621000, Sichuan, P.R.China;
2. Department of Cardiovascular Surgery, West China Hospital, Sichuan University, Chengdu, 610041, P.R.China;

Corresponding author：

HU Jia, Email: humanjia@msn.com

Keywords：

Vein grafts; epigallocatechin-3-gallate; Notch signal pathway; HES1

DOI：

10.7507/1007-4848.201704044

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To investigate the effect and mechanism of epigallocatechin-3-gallate (EGCG) on restenosis of the vein graft. Methods Totally 90 Sprague-Dawley rats were randomly divided a the control group, a vein graft group and an EGCG+vein graft group. At week 1, 2 and 4, the intimal and tunica thickness of the venous graft wall was evaluated by hematoxylin-eosin staining, and the expression of Ki-67 was assessed by immunohistochemistry analysis, and then the expression of hairy and enhancer of split-1 (HES1) was measured by Western blot assay. Results At week 2, the intimal thickness (46.76±4.89 μmvs. 8.93±0.82 μm, 46.76±4.89 μmvs. 34.24±3.57 μm), tunica thickness (47.28±4.37vs. 16.33±1.52 μm, 47.28±4.37vs. 36.27±3.29 μm), positive cell rate of Ki-67 (21.59%±2.29%vs. 1.12%±0.22%, 21.59%±2.29%vs. 15.38%±1.30%), expression of HES1 respectively increased in the experimental group than those in the control group and the EGCG+vein graft group (P<0.05, respectively). At week 4, the intimal thickness (66.38±6.23 μmvs. 8.29±0.79 μm, 66.38±6.23 μmvs. 48.39±4.23 μm), tunica thickness (63.27±6.18 μmvs. 15.29±1.49 μm, 63.27±6.18 μmvs. 44.63±4.49 μm), positive cell rate of Ki-67 (33.19%±3.03%vs. 1.09%±0.19%, 33.19%±3.03%vs. 24.37%±2.73%), expression of HES1 increased in the experimental group than those in the control group and EGCG+vein graft group (P<0.05, respectively). Conclusion EGCG may inhibite restenosis of vein graft by inhibiting Notch signal pathway.

Citation： ZHANG Yi, GU Jun, LIU Linbo, LIAO Zhijie, ZHANG Hongwei, YANG Peng, FAN Kangjun, LIANG Huaimin, XIAO Zhenghua, HU Jia. Inhibitory effect and mechanism of epigallocatechin-3-gallate on autogenous vein graft stenosis in rat models. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2017, 24(10): 791-796. doi: 10.7507/1007-4848.201704044 Copy

1.	Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation, 2011, 124(23): 2610-2642.
2.	Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med, 2009, 360(10): 961-972.
3.	Liu ZH, Dai XM, Du B. Hes1: a key role in stemness, metastasis and multidrug resistance. Cancer Biol Ther, 2015, 16(3): 353-359.
4.	Xiao YG, Wang W, Gong D, et al. γ-secretase inhibitor DAPT attenuates intimal hyperplasia of vein grafts by inhibition of Notch1 signaling. Lab Invest, 2014, 94(6): 654-662.
5.	Yin J, Huang F, Yi Y, et al. EGCG attenuates atherosclerosis through the Jagged-1/Notch pathway. Int J Mol Med, 2016, 37(2): 398-406.
6.	姜春力, 谷天祥. 局部应用没食子儿茶素-3-没食子酸抑制移植静脉内膜增生. 中国动脉硬化杂志, 2005, 13(6): 741-743.0.
7.	胡佳, 古君, 许飞, 等. EGCG 对大鼠心肌缺血再灌注损伤的影响及作用机制探讨. 四川大学学报(医学版), 2016, 47(3): 305-309.0.
8.	Hess CN, Lopes RD, Gibson CM, et al. Saphenous vein graft failure after coronary artery bypass surgery: insights from PREVENT IV. Circulation, 2014, 130:1445-1451.
9.	Perek B, Malinska A, Stefaniak S, et al. Predictive factors of late venous aortocoronary graft failure: ultrastructural studies. PLoS One, 2013, 8(8): e70628.
10.	Hu J, Wan S. External support in preventing vein graft failure. Asian Cardiovasc Thorac Ann, 2012, 20(5): 615-622.
11.	Kim F Y, Marhefka G, Ruggiero N J, et al. Saphenous vein graft disease: review of pathophysiology, prevention, and treatment. Cardiol Rev, 2013, 21(2): 101-109.
12.	George SJ, Wan S, Hu J, et al. Sustained reduction of vein graft neointima formation by ex vivo TIMP-3 gene therapy. Circulation, 2011, 124(11 Suppl): S135-S142.
13.	张洪伟, 肖正华, 张尔永, 等. 血管外支架防治自体静脉桥失效的研究进展. 中华实验外科, 2015; 32(11): 2903-2905.0.
14.	Chakrawarti L, Agrawal R, Dang S, et al. Therapeutic effects of EGCG: a patent review. Expert Opin Ther Pat, 2016, 26(8): 907-916.
15.	Bray SJ. Notch signalling in context. Nat Rev Mol Cell Biol, 2016, 17(11): 722-735.
16.	Zhou X, Xiao Y, Mao Z, et al. Soluble Jagged-1 inhibits restenosis of vein graft by attenuating Notch signaling. Microvasc Res, 2015, 100: 9-16.

1. Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation, 2011, 124(23): 2610-2642.
2. Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med, 2009, 360(10): 961-972.
3. Liu ZH, Dai XM, Du B. Hes1: a key role in stemness, metastasis and multidrug resistance. Cancer Biol Ther, 2015, 16(3): 353-359.
4. Xiao YG, Wang W, Gong D, et al. γ-secretase inhibitor DAPT attenuates intimal hyperplasia of vein grafts by inhibition of Notch1 signaling. Lab Invest, 2014, 94(6): 654-662.
5. Yin J, Huang F, Yi Y, et al. EGCG attenuates atherosclerosis through the Jagged-1/Notch pathway. Int J Mol Med, 2016, 37(2): 398-406.
6. 姜春力, 谷天祥. 局部应用没食子儿茶素-3-没食子酸抑制移植静脉内膜增生. 中国动脉硬化杂志, 2005, 13(6): 741-743.0.
7. 胡佳, 古君, 许飞, 等. EGCG 对大鼠心肌缺血再灌注损伤的影响及作用机制探讨. 四川大学学报(医学版), 2016, 47(3): 305-309.0.
8. Hess CN, Lopes RD, Gibson CM, et al. Saphenous vein graft failure after coronary artery bypass surgery: insights from PREVENT IV. Circulation, 2014, 130:1445-1451.
9. Perek B, Malinska A, Stefaniak S, et al. Predictive factors of late venous aortocoronary graft failure: ultrastructural studies. PLoS One, 2013, 8(8): e70628.
10. Hu J, Wan S. External support in preventing vein graft failure. Asian Cardiovasc Thorac Ann, 2012, 20(5): 615-622.
11. Kim F Y, Marhefka G, Ruggiero N J, et al. Saphenous vein graft disease: review of pathophysiology, prevention, and treatment. Cardiol Rev, 2013, 21(2): 101-109.
12. George SJ, Wan S, Hu J, et al. Sustained reduction of vein graft neointima formation by ex vivo TIMP-3 gene therapy. Circulation, 2011, 124(11 Suppl): S135-S142.
13. 张洪伟, 肖正华, 张尔永, 等. 血管外支架防治自体静脉桥失效的研究进展. 中华实验外科, 2015; 32(11): 2903-2905.0.
14. Chakrawarti L, Agrawal R, Dang S, et al. Therapeutic effects of EGCG: a patent review. Expert Opin Ther Pat, 2016, 26(8): 907-916.
15. Bray SJ. Notch signalling in context. Nat Rev Mol Cell Biol, 2016, 17(11): 722-735.
16. Zhou X, Xiao Y, Mao Z, et al. Soluble Jagged-1 inhibits restenosis of vein graft by attenuating Notch signaling. Microvasc Res, 2015, 100: 9-16.

Previous Article
Early outcomes of totally endoscopic mitral valve repair with artificial chordae implantation
Next Article
Research progress on two types of lung volume reduction

Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Inhibitory effect and mechanism of epigallocatechin-3-gallate on autogenous vein graft stenosis in rat models

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content